Chronic Spontaneous Urticaria Treatment Market is projected to witness substantial growth over the next few years, driven by advancements in treatment modalities and increasing awareness of the condition. The pipeline for Chronic Spontaneous Urticaria Therapeutics includes promising candidates that aim to not only treat acute attacks but also prevent recurrence.
DelveInsight’s “Chronic Spontaneous Urticaria Market Insights, Epidemiology and Market Forecast – 2034” report delivers an in-depth understanding of the Chronic Spontaneous Urticaria, historical and forecasted epidemiology as well as the Chronic Spontaneous Urticaria market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.
Unlock detailed insights into the Chronic Spontaneous Urticaria Market by downloading the comprehensive report from DelveInsight @ Chronic Spontaneous Urticaria Treatment Market Size
Key Takeaways from the Chronic Spontaneous Urticaria Market
- In September 2024:- Celldex Therapeutics- The purpose of this study is to establish the efficacy, safety and tolerability of barzolvolimab in adult participants with Chronic Spontaneous Urticaria (CSU) inadequately controlled by non-sedating second generation H1-antihistamines in comparison to placebo.
- In September 2024:- Taizhou Mabtech Pharmaceutical Co.,Ltd- This study is a multicenter, randomized, double-blind, positive parallel controlled phase III clinical trial to compare efficacy, immunogenicity, pharmacokinetics, pharmacodynamics and safety of omalizumab α(CMAB007) and Xolair® in patients with refractory chronic spontaneous urticaria.
- The increase in Chronic Spontaneous Urticaria Market Size is a direct consequence of expected approval of emerging therapies and increasing awareness of chronic spontaneous urticaria in the 7MM.
- As per DelveInsight analysis, there were approximately 4.1 million diagnosed prevalent cases of chronic urticaria, in the 7MM, in 2023. These cases are projected to increase during the forecast period (2024-2034).
- According to DelveInsight analysis, there were around 138 thousand male and 381 thousand female cases of chronic spontaneous urticaria (CSU) in the US in 2023, with numbers expected to rise by 2034.
- As per DelveInsight analysis among EU4 and the UK, there was a higher female affected population e.g. Germany accounted for around 97 thousand males and 229 thousand females affected by CSU in 2023. These cases are expected to change during the forecast period (2024-2034).
- As per DelveInsight’s epidemiology model, among EU4 and the UK, the ≥60 age group had the highest number of CSU cases contributing to nearly 31% of the total cases, while the
- The leading Chronic Spontaneous Urticaria Companies such as Roche, Novartis, Sanofi Pharmaceutical, Genentech, AstraZeneca, Kiniksa Pharmaceuticals, Ltd, United BioPharma, GlaxoSmithKline, Allakos, Eli Lilly and Company and others.
- Promising Chronic Spontaneous Urticaria Therapies such as barzolvolimab, CMAB007, Xolair, Dupilumab, LOU064 (blinded), and others.
Gain a competitive edge in the Chronic Spontaneous Urticaria Market by exploring our in-depth analysis. Visit our website to access the full report and make informed strategic decisions @ Chronic Spontaneous Urticaria Treatment Drugs
Chronic Spontaneous Urticaria Epidemiology Segmentation in the 7MM
- Total Chronic Spontaneous Urticaria Diagnosed Prevalent Cases
- Chronic Spontaneous Urticaria Type-specific Cases
- Chronic Spontaneous Urticaria Gender-specific Cases
- Chronic Spontaneous Urticaria Age-specific Cases
- Chronic Spontaneous Urticaria Severity-specific Cases
Chronic Spontaneous Urticaria Treatment Market
The treatment of CSU is challenging, and the therapeutic goal is a reduction in disease activity, complete symptom control, and improvement in QoL. The current treatment regime aims to alleviate symptoms and prevent their recurrence. The treatment pattern typically involves a step-wise approach, starting with first-line treatments and progressing to more advanced options if necessary. Treatment is generally initiated with nonsedating antihistamines in the daytime and sedating antihistamines at night. H2-antihistamines are often combined with H1 to achieve better symptom control in CSU and are added if individuals complain of indigestion or acidity. The most commonly used H2 antihistamine for CSU is ranitidine. However, it is important to note that ranitidine has been withdrawn from many markets due to safety concerns. Many patients, however, do not achieve symptom control, with only less than half of patients responding to H1-antihistamines at standard doses. Adverse effects such as somnolence can occur in susceptible individuals, increasing the treatment burden, despite increasing the dose.
Discover key developments and opportunities in the Chronic Spontaneous Urticaria Market. Click here to learn more from DelveInsight’s latest report @ Chronic Spontaneous Urticaria Market Size
Chronic Spontaneous Urticaria Marketed Drugs
- XOLAIR (omalizumab): Roche/Novartis
- DUPIXENT (dupilumab): Sanofi/Regeneron
Chronic Spontaneous Urticaria Emerging Drugs Profile
- Remibrutinib (LOU064): Novartis Pharmaceuticals
- TEZSPIRE (tezepelumab): AstraZeneca/Amgen
- Rilzabrutinib (SAR444671): Sanofi
Chronic Spontaneous Urticaria Therapeutics Market Landscape
Chronic spontaneous urticaria is a chronic condition characterized by the recurrent appearance of hives or wheals on the skin. It is a disturbing allergic condition of the skin, where symptoms persist for more than 6 weeks. The diagnosis is based on a physical examination and medical history. Additional tests are performed to rule out underlying causes or to identify triggers, such as blood tests, allergy tests, or skin biopsies. Treating chronic spontaneous urticaria is challenging, and the therapeutic goal is a reduction in disease activity, complete symptom control, and improvement in QoL. The current treatment regime aims to alleviate symptoms and prevent their recurrence. The treatment pattern typically involves a stepwise approach, starting with first-line treatments and progressing to more advanced options if necessary.
Chronic Spontaneous Urticaria Market Outlook
Chronic spontaneous urticaria is a disturbing allergic condition of the skin where symptoms persist for more than 6 weeks. A mast cell-driven disease is characterized by recurrent itchy wheals (hives) that may accompany angioedema. It often causes huge socio-economic distress for the patients, significantly impacting their quality of life. Treating chronic spontaneous urticaria is challenging, and the therapeutic goal is a reduction in disease activity, complete symptom control, and improvement in QoL. The current treatment regime aims to alleviate symptoms and prevent their recurrence. The treatment pattern typically involves a stepwise approach, starting with first-line treatments and progressing to more advanced options if necessary.
Download DelveInsight’s Chronic Spontaneous Urticaria Market report today and stay ahead in this rapidly evolving field. @ Chronic Spontaneous Urticaria Clinical Trials
Scope of the Chronic Spontaneous Urticaria Market Report
- Coverage- 7MM
- Chronic Spontaneous Urticaria Companies- Roche, Novartis, Sanofi Pharmaceutical, Genentech, AstraZeneca, Kiniksa Pharmaceuticals, Ltd, United BioPharma, GlaxoSmithKline, Allakos, Eli Lilly and Company and others.
- Chronic Spontaneous Urticaria Therapies- Barzolvolimab, CMAB007, Xolair, Dupilumab, LOU064 (blinded), and others.
- Chronic Spontaneous Urticaria Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
- Chronic Spontaneous Urticaria Unmet Needs, KOL’s views, Analyst’s views, Chronic Spontaneous Urticaria Market Access and Reimbursement
Download the report to understand which factors are driving Chronic Spontaneous Urticaria Market Trends @ Chronic Spontaneous Urticaria Market Trends
Table of Content
1. Key Insights
2. Report Introduction
4. Methodology of Chronic Spontaneous Urticaria Epidemiology and Market
5. Executive Summary of Chronic Spontaneous Urticaria
6. Key Events
7. Disease Background and Overview
8. Patient Journey
9. Epidemiology and Patient Population
10. Marketed Drugs
11. Emerging Drugs
12. Chronic Spontaneous Urticaria: Market Analysis
13. Key Opinion Leaders’ Views
14. SWOT
15. Unmet needs
16. Market Access and Reimbursement
17. Appendix
18. DelveInsight Capabilities
19. Disclaimer
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
Press Release Distributed by ABNewswire.com
To view the original version on ABNewswire visit: Chronic Spontaneous Urticaria Treatment Market Size in the 7MM was ~USD 2200 Million in 2023, estimated DelveInsight